Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Simon Green

  • Home
  •  
  • Simon Green



  • Most Read
  • Latest Comments
  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AVITA Medical to collaborate with Regenity Biosciences to expand their skin regeneration portfolio
    AVITA Medical to collaborate with Regenity Biosciences to expand their skin regeneration portfolio
    • News

  • Syntara partners with University of Newcastle and ALLG to reduce blood transfusion dependence in blood cancer patients
    Syntara partners with University of Newcastle and ALLG to reduce blood transfusion dependence in blood cancer patients
    • News

  • Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%
    Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%
    • News

  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    • News

  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    • News

    Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development

    Clinical-stage biotech company Syntara (ASX: SNT) has stepped into a transformative year with a renewed focus on drug development. Entering 2024, the Company took the “new year, new me” concept seriously, divesting its Pharmaxis mannitol business and rebranding as Syntara with new leadership to include high profile biotech experts that have commercialised drugs for Big

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.